Evidence map›Paper›PMID 28956073›Full record

ArticleHerz2018

Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits : An

J Xu, M Nie, J Li, Z Xu, M Zhang, Y Yan, T Feng, X Zhao, Q Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in Herz, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Regulatory Role of Sex Hormones in Cardiovascular Calcification.International journal of molecular sciences · 2021
    Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

J XuBeijing Anzhen Hospital, Capital Medical University, Anzhen Road, Chaoyang District, 100029, Beijing, China.
M NieBeijing Anzhen Hospital, Capital Medical University, Anzhen Road, Chaoyang District, 100029, Beijing, China.
J LiAffiliated Hospital of Hebei University, Yuhua East Road No. 212, 071000, BaoDing, HeBei, China.
Z XuAffiliated Hospital of Hebei University, Yuhua East Road No. 212, 071000, BaoDing, HeBei, China.
M ZhangBeijing Anzhen Hospital, Capital Medical University, Anzhen Road, Chaoyang District, 100029, Beijing, China.
Y YanBeijing Anzhen Hospital, Capital Medical University, Anzhen Road, Chaoyang District, 100029, Beijing, China.
T FengBeijing Anzhen Hospital, Capital Medical University, Anzhen Road, Chaoyang District, 100029, Beijing, China.
X ZhaoBeijing Anzhen Hospital, Capital Medical University, Anzhen Road, Chaoyang District, 100029, Beijing, China.
Q ZhaoBeijing Anzhen Hospital, Capital Medical University, Anzhen Road, Chaoyang District, 100029, Beijing, China. zhaoquanming1@sina.com.ORCID http://orcid.org/0000-0003-3457-4953
Capital Medical University · CNAffiliated Hospital of Hebei University · CN

Funding

Beijing Natural Science Foundation of China No. 7132078National Natural Science Foundation of China No. 81370437"Twelve Five" National Key Technology R & D Program of China No. 2011BAI11B05
6 · The paper itself

Abstract

backgroundWe developed an atherosclerotic rabbit model and tested pioglitazone as a drug intervention for early vascular calcification. Positron emission tomography/computed tomography (PET/CT) was used to evaluate inflammation and therapeutic effects.

methodsWe randomly divided 20 male New Zealand white rabbits into a pioglitazone-treated group (n = 10) and a control group (n = 10). Atherosclerosis was induced via a high-cholesterol diet and endothelial denudation. The animals were maintained on a hyperlipidemic diet for 16 weeks after surgery, and the treatment group received pioglitazone daily. Serum samples were obtained at 8 and 18 weeks postoperatively to assess high-sensitivity C‑reactive protein (hs-CRP) and matrix metalloproteinase-9 (MMP-9) concentrations. Sixteen rabbits underwent a mid-stage PET/CT scan at week 8, and 11 rabbits underwent an end-stage PET/CT scan at week 18. PET/CT parameters, including the mean standardized uptake value (SUVmean) and maximum standardized uptake value (SUVmax), were measured and documented.

resultsThere were significantly lower hs-CRP and MMP-9 levels in the pioglitazone group at week 18 (p < 0.01). At the end of the 8th week, no significant between-group differences in SUVmean and SUVmax were observed. From week 8 to week 18, the SUVmean and SUVmax decreased in the pioglitazone group but the SUVmean increased in the control group, with significant between-group differences at the end of the 18th week (p < 0.01). Histopathological examination of aortas in the control and pioglitazone groups revealed significantly smaller plaque area, macrophage density, and tissue calcification area in the latter group.

conclusionPioglitazone affects early vascular microcalcification, and pioglitazone-induced changes can be assessed using

Indexed as

AtherosclerosisCalcinosisHypoglycemic AgentsInflammationPioglitazoneAnimalsFluorodeoxyglucose F18MalePositron-Emission TomographyPositron Emission Tomography Computed TomographyRabbitsRandom AllocationTomography, X-Ray ComputedFluorodeoxyglucose F18Hypoglycemic AgentsPioglitazoneAtherosclerotic plaqueCoronary artery diseaseHypoglycemic agentsPositron emission tomography-computed tomographyVascular calcification

Identifiers

PMID28956073
OpenAlexW2765373362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.